ETIOLOGY, DIAGNOSIS, AND MANAGEMENT OF POLYMORPHIC ERUPTION OF PREGNANCY

Polymorphic Eruption of Pregnancy (PEP), historically and often interchangeably termed Pruritic Urticarial Papules and Plaques of Pregnancy (PUPPP), is the most common specific dermatosis to affect gestation, causing significant maternal morbidity due to intense pruritus. While generally benign, its presentation often necessitates careful differentiation from other serious pregnancy-related skin conditions.

Introduction and Etiology of Polymorphic Eruption of Pregnancy

Polymorphic Eruption of Pregnancy is a late-onset, highly pruritic cutaneous disorder affecting approximately 1 in 160 to 1 in 300 pregnancies. PEP is predominantly observed in primigravid women (first pregnancy) and is strongly associated with conditions resulting in rapid and extensive abdominal distension, such as multiple gestation (twins or triplets) and excessive maternal or fetal weight gain, suggesting a mechanical contribution to its pathophysiology.

Terminology and Definition

The term Polymorphic Eruption of Pregnancy (PEP) is preferred in contemporary literature as the lesions are not always strictly urticarial and the term encompasses the full spectrum of morphological findings. It is characterized by the sudden onset of intensely itchy papules and plaques, almost exclusively confined to the abdominal skin and often sparing the periumbilical region at initial onset.

Proposed Etiological Theories

The precise pathogenesis of PEP remains elusive, but several compelling theories relate to the mechanical and immunological changes inherent to pregnancy:

1. Mechanical Stress and Connective Tissue Damage: The most widely accepted theory posits that massive and rapid abdominal distension in the third trimester leads to significant stretching and mechanical damage to the dermal collagen and elastic fibers, particularly within the abdominal striae distensae (stretch marks). This damage is hypothesized to trigger a localized inflammatory response. Histological studies often show changes (e.g., mucin deposition and degradation of elastic fibers) consistent with trauma preceding the inflammatory cascade.

2. Trophoblastic Microchimerism and Immune Response: A more complex theory involves the presence of fetal cells (male microchimerism) persisting in maternal tissues. Studies have suggested an increased prevalence of male fetuses in PEP cases, although this observation is inconsistent across all populations. It is hypothesized that a localized maternal immune reaction against paternal or fetal antigens deposited in the skin’s connective tissue might initiate the eruption.

3. Hormonal Influences: Though less strongly supported than the mechanical theory, the high estrogen and progesterone levels characteristic of late pregnancy may influence mast cell activity and vascular permeability, contributing to the development of the urticarial phase of the eruption.

Symptoms and Signs of Polymorphic Eruption of Pregnancy (Clinical Presentation)

The clinical hallmark of PEP is its polymorphic nature—meaning the rash presents in multiple forms simultaneously—and its characteristic pattern of distribution. The onset is typically rapid, occurring late in the third trimester (mean onset around 35 weeks gestation) or, less commonly, immediately postpartum. The eruption rarely occurs before the third trimester.

A. Subjective Symptoms: Pruritus

Intense itching (pruritus) is the dominant and most distressing feature. The severity of the pruritus can be debilitating, often interfering with sleep, concentration, and overall quality of life. The severity is often disproportionate to the mild appearance of the early rash.

B. Morphology and Development of Lesions

The rash evolves through several distinct phases, justifying the term “polymorphic”:

1. Initial Lesions (Urticarial Phase): The eruption typically begins as small, red, intensely pruritic papules (small, solid, raised bumps) concentrated within the abdominal striae. These rapidly coalesce into large, erythematous, edematous plaques (elevated flat-topped lesions). These plaques are classically described as urticarial, resembling hives.
2. Polymorphic Evolution: As the condition progresses, the lesions diversify, incorporating other morphologies:
   • Vesicles: Small, clear fluid-filled blisters (less than 5 mm) may appear, particularly at the periphery of plaques. The presence of large bullae (blisters greater than 1 cm) is not characteristic and suggests an alternative diagnosis, such as Pemphigoid Gestationis.
   • Target Lesions: Occasional lesions may resemble erythema multiforme.
   • Eczematous and Targetoid Lesions: Crusting, excoriations (due to scratching), and secondary eczematous changes often overlie the primary lesions.
3. Distribution: The distribution pattern is highly characteristic and serves as a vital diagnostic clue:
   • Inception Site: Almost always begins on the abdomen, specifically sparing the periumbilical area (the skin immediately surrounding the navel) initially.
   • Spread: The eruption subsequently spreads centripetally to the thighs, buttocks, proximal extremities (arms and legs closest to the torso), and sometimes the back.
   • Sparing: Lesions rarely extend above the breasts or involve the palms, soles, or face. This sparing of the face, mucous membranes, and periumbilical area is crucial for distinguishing PEP from other dermatoses.

Diagnosis of Polymorphic Eruption of Pregnancy

The diagnosis of PEP is primarily clinical, based on the characteristic morphology, distribution, and timing of onset. However, due to the intense pruritus and the potential for overlap with far more serious conditions, diagnostic testing is often mandatory, primarily to exclude other dermatoses.

A. Clinical Diagnostic Criteria

Diagnosis requires the presence of the following key features:

1. Onset in the late third trimester or immediate postpartum period.
2. Presence of pruritic, erythematous papules and plaques.
3. Initial development within the abdominal striae.
4. Sparing of the periumbilical region (usually).
5. Absence of severe systemic symptoms (e.g., fever, malaise).
6. Lack of primary involvement of the palms, soles, or face.

B. Role of Histopathology

A punch biopsy from a representative lesion (a fresh papule or the edge of a plaque) can support the diagnosis and help in excluding T-cell lymphomas or severe drug eruptions.

• Key Histological Findings: Non-specific, characterized by a superficial, perivascular, lymphohistiocytic infiltrate (inflammatory cells clustered around small blood vessels) in the dermis. There is often mild focal spongiosis (edema in the epidermis) and eosinophils (a type of white blood cell) are commonly present in the infiltrate, although their presence is not universal. Critically, there is no significant epidermal necrosis or subepidermal blistering.

C. Differential Diagnosis and Exclusionary Testing

The most critical step in establishing the diagnosis is ruling out conditions that pose risks to maternal or fetal health. This is typically achieved through immunofluorescence studies and laboratory screening.

Treatment of Polymorphic Eruption of Pregnancy (Step-by-Step Management)

The management goals for PEP are centered on alleviating the severe pruritus, improving the maternal quality of life, and preventing secondary infection from scratching. Treatment is entirely symptomatic, as the condition is self-limiting and resolves spontaneously within 1 to 4 weeks postpartum.

A tiered therapeutic approach is utilized, escalating treatment based on the severity of the pruritus and extent of the eruption.

Step 1: Supportive and Topical Therapy (Mild/Localized PEP)

For mild cases where the rash is localized and itching is tolerable, conservative measures are the mainstay.

A. Non-Pharmacological Interventions:

• Cool Compresses and Baths: Applying cool, wet wraps or taking lukewarm baths, often with added colloidal oatmeal (Aveeno), can provide temporary relief by soothing the inflamed skin.
• Emollients and Moisturizers: Regular use of bland emollients aids in hydrating the skin barrier and reducing dryness, which can exacerbate itching.
• Avoidance of Exacerbating Factors: Patients should be advised to wear loose-fitting, cotton clothing and avoid excessive heat, which can worsen pruritus.

B. Topical Corticosteroids (First-line Pharmacotherapy): Topical corticosteroids are the most effective initial treatment. The potency is chosen based on the area treated and the severity of inflammation.

• Medium-Potency Steroids: (e.g., Triamcinolone 0.1% cream or ointment) applied two to three times daily are standard for treating the thick plaques on the trunk and extremities.
• High-Potency Steroids: (e.g., Clobetasol 0.05% or Betamethasone Dipropionate 0.05%) may be used judiciously for severe, localized plaques for short durations (less than 2 weeks) before tapering. High-potency steroids should be used cautiously on large surface areas due to the theoretical risk of systemic absorption, although this risk is low when used appropriately.

Step 2: Oral Adjunctive Therapy (Moderate PEP)

If pruritus is severe enough to disturb sleep or if the eruption is generalized, systemic medications are introduced alongside topical treatments.

A. Systemic Antihistamines: H1-receptor antagonists are used primarily for their sedative effects, which help interrupt the scratch-itch cycle and improve sleep, rather than their direct anti-pruritic mechanism (as histamine is not the primary mediator of PEP pruritus).

• Sedating Antihistamines: Diphenhydramine (Benadryl) or Hydroxyzine are often prescribed at bedtime.
• Non-Sedating Antihistamines: Loratadine or Cetirizine can be used during the day if daytime sedation is a concern, though their efficacy against PEP pruritus is often limited. All common H1 antihistamines are generally categorized as low-risk in the second and third trimesters.

Step 3: Systemic Corticosteroids (Severe/Refractory PEP)

Oral corticosteroids are reserved for patients with widespread, severely symptomatic PEP refractory to topical management and antihistamines.

• Rationale: Oral steroids provide potent, rapid anti-inflammatory and immunosuppressive effects, often leading to dramatic symptomatic improvement within 24–48 hours.
• Regimen: Prednisone or Prednisolone is typically initiated at a moderate dose (e.g., 20–40 mg/day). Given the late timing of PEP onset, the risks associated with systemic glucocorticoid use (e.g., oral cleft development, which is a concern in the first trimester) are minimal.
• Tapering: The dose must be tapered slowly over 7 to 10 days to prevent rebound flaring of the eruption. Rapid tapering should be avoided. A typical course rarely exceeds 14 days.

Note on Fetal Safety: Corticosteroids, particularly prednisone, are largely metabolized by the placenta (converted to inactive cortisone), minimizing direct fetal exposure. This makes them a relatively safe option for short-term use in the third trimester when medically necessary.

Prognosis and Fetal/Maternal Outcomes

Maternal Prognosis

PEP is universally benign, posing no long-term threat to the mother. While intense, the eruption typically resolves completely and spontaneously within 1–4 weeks after delivery, often immediately before or within a few days of delivery. Residual hyperpigmentation (darkening of the skin) may persist temporarily at the former site of the plaques, but scarring does not occur. The condition does not predispose the patient to other chronic skin conditions.

• Recurrence Risk: Recurrence in subsequent pregnancies is low (estimated at less than 5%) and is almost negligible compared to the high recurrence rate associated with Pemphigoid Gestationis. Recurrences, if they occur, are usually milder.

Fetal Prognosis

Crucially, PEP has been consistently demonstrated to have no adverse effects on the fetus. Unlike Intrahepatic Cholestasis of Pregnancy (ICP) or Pemphigoid Gestationis (PG), PEP is not associated with increased risk of fetal mortality, preterm birth, low birth weight, or placental insufficiency. Treatment administered for PEP (topical steroids, antihistamines, and short courses of oral steroids) is also considered safe for the developing fetus during the late third trimester.

Conclusion

Polymorphic Eruption of Pregnancy is the most prevalent cause of severe pruritus-related skin disease in the third trimester. While the cause is generally attributed to rapid abdominal distension and mechanical factors, the resulting intense immune-mediated inflammation necessitates effective symptomatic treatment. Diagnosis rests upon the characteristic clinical presentation—namely, the urticarial plaques originating in the striae and sparing the periumbilical region—and crucially relies on the exclusion of Pemphigoid Gestationis and Intrahepatic Cholestasis of Pregnancy through laboratory and immunological testing. Management is stepwise, progressing from topical corticosteroids and supportive measures to the use of systemic corticosteroids for severe, refractory cases, ensuring maternal comfort until spontaneous resolution occurs postpartum. PEP is a benign condition, and patients can be thoroughly reassured regarding the favorable fetal prognosis.

References

1. Ambros-Rudolph, C. M., Müllegger, R. R., Vaughan-Jones, S. A., Kerl, H., & Black, M. M. (2006). The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective analysis of 500 pregnant women. Journal of the American Academy of Dermatology, 54(3), 393–400.
2. Kroumpouzos, G., & Cohen, L. M. (2001). Specific dermatoses of pregnancy: an evidenced-based approach to diagnosis and management. American Journal of Clinical Dermatology, 2(3), 183–192.
3. Lawley, T. J., Hertz, K. C., Wade, T. R., Ackerman, A. B., & Katz, S. I. (1979). Pruritic urticarial papules and plaques of pregnancy. Journal of the American Academy of Dermatology, 1(1), 13–21.
4. Rudolph, C. M., & Ambros-Rudolph, C. M. (2020). Pruritic urticarial papules and plaques of pregnancy (PUPPP) or polymorphic eruption of pregnancy (PEP). In L. S. Goldberg & C. M. Rudolph (Eds.), Dermatology in Pregnancy (pp. 209-216). Springer.
5. VAERS, U. S. (2022). Polymorphic Eruption of Pregnancy. Dermatology Online Journal.
6. Winton, G. B., & Lewis, C. W. (1982). Dermatoses of pregnancy. Journal of the American Academy of Dermatology, 6(2), 977–998.